autologous mesoangioblasts

Autologous mesoangioblasts (MABs) are a type of vessel-associated progenitor cell, specifically pericyte-derived, that are isolated from a patient's own skeletal muscle biopsy. These cells are expanded *in vitro* and re-administered to the patient, typically via intra-arterial delivery, to promote muscle regeneration and functional recovery. In the context of mitochondrial myopathy (such as the m.3243A>G mutation), the therapy aims to select and expand mesoangioblasts with a low mutation heteroplasmy load. Once delivered to the affected muscle, these cells can cross the vessel wall, differentiate into new muscle fibers, and potentially restore mitochondrial function and muscle strength while reducing fatigue. The development of this therapy is primarily led by academic institutions, notably Maastricht University, following foundational research into mesoangioblast biology for muscular dystrophies.

Other names

autologous MABsmesoangioblasts